Display options
Cite
Quiroga-García V, Cirauqui-Cirauqui B, Bugés-Sánchez C, et al. Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients. Breast Care (Basel). 2015;10(3):179-83doi: 10.1159/000382112.
Quiroga-García, V., Cirauqui-Cirauqui, B., Bugés-Sánchez, C., Luna-Tomás, M. �. �., Castellà-Fernández, E. M., Mariscal-Martínez, A., & Margelí-Vila, M. (2015). Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients. Breast care (Basel, Switzerland), 10(3), 179-83. https://doi.org/10.1159/000382112
Quiroga-García, Vanesa, et al. "Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients." Breast care (Basel, Switzerland) vol. 10,3 (2015): 179-83. doi: https://doi.org/10.1159/000382112
Quiroga-García V, Cirauqui-Cirauqui B, Bugés-Sánchez C, Luna-Tomás MÁ, Castellà-Fernández EM, Mariscal-Martínez A, Margelí-Vila M. Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients. Breast Care (Basel). 2015 Jul;10(3):179-83. doi: 10.1159/000382112. Epub 2015 May 22. PMID: 26648829; PMCID: PMC4670958.
Copy Download .nbib Format: NLM
Share it on

Breast Care (Basel). 2015 Jul;10(3):179-83. doi: 10.1159/000382112. Epub 2015 May 22.

Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients.

Breast care (Basel, Switzerland)

Vanesa Quiroga-García, Beatriz Cirauqui-Cirauqui, Cristina Bugés-Sánchez, Miguel Ángel Luna-Tomás, Eva María Castellà-Fernández, Antonio Mariscal-Martínez, Mireia Margelí-Vila

Affiliations

  1. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
  2. Gynecology and Obstetrics Service, Hospital Germans Trias i Pujol, Badalona, Spain.
  3. Pathology Service, Hospital Germans Trias i Pujol, Badalona, Spain.
  4. Radiology Service, Hospital Germans Trias i Pujol, Badalona, Spain.

PMID: 26648829 PMCID: PMC4670958 DOI: 10.1159/000382112

Abstract

BACKGROUND: Treatment with aromatase inhibitors (AIs) followed by surgery is often recommended for women with locoregional hormone-sensitive breast cancer. However, no study has compared the efficacy of AIs alone versus AIs followed by surgery.

METHODS: 33 postmenopausal breast cancer patients were treated with primary hormone therapy. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor type 2 receptor (HER2) expression levels were analyzed by immunohistochemistry. After hormone therapy, eligible patients underwent surgery, and those who were not candidates for surgery continued on hormone therapy. We retrospectively analyzed time to progression, overall survival, response, and impact of surgery on outcome.

RESULTS: All patients were ER+. HER2 was successfully analyzed in 30 patients, all of whom were HER2-. The median time to progression was 94 months, and the median overall survival was not reached, while the mean overall survival was 123 months. The overall response rate was 63.6%, with 9.1% complete responses. No significant differences in time to progression or survival were observed between patients who underwent surgery and those who did not.

CONCLUSIONS: Primary hormone therapy with AIs is effective in elderly breast cancer patients with high levels of hormone receptors and may provide a feasible and tolerable alternative to surgery in selected hormone-sensitive breast cancer patients.

Keywords: ER/PR+/HER2–; Hormone therapy; Locoregional breast cancer; Surgery

References

  1. CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 - PubMed
  2. JAMA. 2001 Feb 21;285(7):885-92 - PubMed
  3. Ann Oncol. 2001 Nov;12(11):1527-32 - PubMed
  4. Science. 1987 Jan 9;235(4785):177-82 - PubMed
  5. Breast. 2003 Oct;12 (5):320-7 - PubMed
  6. Breast Cancer Res Treat. 2007;105 Suppl 1:33-43 - PubMed
  7. Clin Transl Oncol. 2009 Jun;11(6):363-75 - PubMed
  8. Br J Cancer. 2009 Feb 10;100(3):442-9 - PubMed
  9. J Clin Oncol. 2005 Aug 1;23(22):5108-16 - PubMed
  10. Oncologist. 2006 Nov-Dec;11(10 ):1081-8 - PubMed
  11. Br J Surg. 2004 Jun;91(6):699-704 - PubMed
  12. Br J Cancer. 1987 Jan;55(1):61-6 - PubMed
  13. N Engl J Med. 2006 Jan 19;354(3):270-82 - PubMed
  14. J Clin Oncol. 2011 Jun 10;29(17 ):2342-9 - PubMed
  15. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  16. Mod Pathol. 1998 Feb;11(2):155-68 - PubMed
  17. Breast Cancer Res Treat. 2009 Jul;116(2):371-8 - PubMed
  18. Int J Cancer. 2010 Dec 15;127(12):2893-917 - PubMed
  19. Cancer Control. 2000 Nov-Dec;7(6):557-62 - PubMed
  20. Cancer. 2007 Jul 15;110(2):244-54 - PubMed
  21. Ann Oncol. 2003 Mar;14(3):414-20 - PubMed
  22. Cancer. 1989 Mar 1;63(5):976-81 - PubMed

Publication Types